Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
2395 Stock Chart & Stats
¥1622.00
¥20.00(1.21%)
At close: 4:00 PM EST
¥1622.00
¥20.00(1.21%)
Day’s Range― - ―
52-Week Range¥1,198.00 - ¥2,005.00
Previous CloseN/A
Volume203.40K
Average Volume (3M)231.41K
Market Cap
¥63.07B
Enterprise Value¥89.19B
Total Cash (Recent Filing)¥11.57B
Total Debt (Recent Filing)¥36.58B
Price to Earnings (P/E)14.4
Beta0.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.79%
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)1.49
Price to Sales (P/S)1.84
P/FCF Ratio-15.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,745.00Price Target Upside69.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent positive revenue growth indicates durable demand for outsourced R&D services. As a CRO with contracted, milestone‑based work, steady top‑line expansion supports capacity utilization and scale, underpinning more predictable cash flows and reinvestment ability over the next 2–6 months.
High Gross MarginA gross margin persistently above 50% reflects structural cost efficiency and pricing power in specialized nonclinical and clinical services. High gross margins provide a durable buffer against rising operating costs and support reinvestment in capabilities without immediately eroding core profitability.
Cash ConversionStrong operating cash conversion shows the business reliably turns reported profits into cash, typical of milestone and fee‑based CRO models. This operational cash strength supports working capital needs and targeted capex, reducing short‑term reliance on external financing despite other cash flow pressures.
Bears Say
Declining Net MarginsA falling net margin erodes the company’s ability to retain earnings and fund growth internally. If the decline reflects structural cost pressures, pricing weakness, or higher SG&A, it can meaningfully reduce financial flexibility and resilience across the next several months.
Rising LeverageIncreasing debt levels raise interest and refinancing risk and constrain strategic optionality. For a services firm dependent on contract wins, higher leverage reduces the buffer against revenue variability and may limit the firm's ability to invest in labs or acquisitions without raising additional capital.
Negative Free Cash FlowRepeated negative free cash flow suggests capex or working capital use outpaces operating cash available for discretionary uses. Persisting negative FCF can force reliance on external funding, increase cost of capital, and constrain investment in capability expansion or shareholder returns over the medium term.
Shin Nippon Biomedical Laboratories, Ltd. News
2395 FAQ
What was Shin Nippon Biomedical Laboratories, Ltd.’s price range in the past 12 months?
Shin Nippon Biomedical Laboratories, Ltd. lowest stock price was ¥1198.00 and its highest was ¥2005.00 in the past 12 months.
What is Shin Nippon Biomedical Laboratories, Ltd.’s market cap?
Shin Nippon Biomedical Laboratories, Ltd.’s market cap is ¥63.07B.
When is Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shin Nippon Biomedical Laboratories, Ltd.’s earnings last quarter?
Currently, no data Available
Is Shin Nippon Biomedical Laboratories, Ltd. overvalued?
According to Wall Street analysts Shin Nippon Biomedical Laboratories, Ltd.’s price is currently Undervalued.
Does Shin Nippon Biomedical Laboratories, Ltd. pay dividends?
Shin Nippon Biomedical Laboratories, Ltd. pays a Semiannually dividend of ¥30 which represents an annual dividend yield of 2.79%. See more information on Shin Nippon Biomedical Laboratories, Ltd. dividends here
What is Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate?
Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shin Nippon Biomedical Laboratories, Ltd. have?
Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding.
What happened to Shin Nippon Biomedical Laboratories, Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shin Nippon Biomedical Laboratories, Ltd.?
Currently, no hedge funds are holding shares in JP:2395
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
2395 Stock 12 Month Forecast
Average Price Target
¥2,745.00
▲(69.24% Upside)
Technical Analysis
Options Prices
Currently, No data available
---